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The Great East Japan Earthquake and tsunami onMarch 11, 2011,
resulted in the Fukushima nuclear power plant accident, which
consequently led to a massive emission of radioactive substances.
Although it is important to know how the disaster affects the vic-
tims' health status, the number of reports on lung diseases are
limited.1,2 We investigate the effect of the disaster on patients
with pulmonary alveolar proteinosis (PAP), who were admitted to
Fukushima Medical University Hospital, located 57 km away from
the Fukushima Daiichi Nuclear Power Plant. Participants gave writ-
ten informed consent and the Fukushima Medical University Ethics
Committee approved this study.
PAP is a rare pulmonary disease characterized by abnormal
accumulation of surfactant lipids and protein in the alveolar spaces
resulting in impairment of gas exchange.3 Signaling by granulocyte-
macrophage colony-stimulating factor (GM-CSF), which is critical
for surfactant homeostasis by alveolar macrophages in the lungs,
is impaired in PAP. In the majority of patients with PAP, GM-CSF au-
toantibodies, which decrease GM-CSF bioactivity, were present in
the serum and bronchoalveolar lavage (BAL) ﬂuid, and PAP with
the antibody is considered to be autoimmune PAP (aPAP).4
Although detailed pathogenesis of PAP is still unknown, Hisata
et al. reported a patient who developed PAP following dust expo-
sure after the Great East Japan Earthquake.5 This ﬁnding prompted
us to investigate whether the Fukushima disaster increased the
number of aPAP patients.
We reviewed patients with aPAP who had been admitted to our
hospital retrospectively, and the prevalence of the patients before
and after Fukushima disaster was evaluated. PAP was diagnosed
by the characteristic ﬁndings of chest high resolution computed to-
mography, BAL ﬂuid withmilk-like appearance and pathologic and/
or cytologic specimens obtained by a transbronchial lung biopsy. In
patients with PAP, serum levels of GM-CSF autoantibody were
analyzed, and patients with diseases known to cause PAP, such as
hematological malignancy, were excluded. We next compared clin-
ical characteristics, such as laboratory data and pulmonary function
tests between the patients who developed aPAP, before and after
the disaster.
In the four years prior to the disaster, the number of patients
with aPAP was only one out of 387 patients with interstitial lung
diseases. On the other hand, in the four years following the disaster,
the number of aPAP patients was seven out of 386 interstitial lungPeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).disease patients, showing a signiﬁcant increase (0.35 vs 1.85%,
p < 0.05). The place of residence of the aPAP patients at the time
of the earthquake was not regarded as an impacting factor for the
disease. Because we had only one aPAP patient before the disaster,
it is difﬁcult to compare the exact difference in clinical characteris-
tics of the aPAP patients before and after the disaster. However, it
seems that the clinical condition of the aPAP patients who devel-
oped after the disaster was possibly more severe on admission, as
such patients had lower partial arterial oxygen pressure and vital
capacity % predicted and higher serum Krebs von den lungen-6,
compared with the patient who was observed before the disaster
(Table 1). On the other hand, the titer of the GM-CSF antibody
measured on admission was not different between the patients
who developed aPAP before and after the disaster (32.5 and
30.3 ± 5.6 ug/ml, respectively). With regard to the clinical course
of the patients who developed aPAP after the disaster, ﬁve patients
(71.4%) were clinically improved during follow-up. Because 42.5% of
patients has been reported to be improved in a large Japanese
cohort of 223 aPAP patients,4 it may be possible that the clinical
course was not severe in the patients who developed aPAP after
the disaster.
In the Hisata et al. report of the 63-year-old Japanese woman
who developed PAP from dust exposure after the Great East Japan
Earthquake,5 the patient visited a devastated neighborhood
without a protective mask and repeatedly inhaled dust. Three
weeks after the earthquake, she developed a dry cough and was
diagnosed as having PAP. In addition, Tsuchiya et al., reported a
case inwhich a 41-year-old Japanese man had developed PAP after
the Great Hanshin Earthquake in 1995.6 He was involved in build-
ing demolition and also inhaled dust. Both reports suggest the
possibility of dust exposure after a disaster being a cause of PAP
development. In fact, the relationship between secondary PAP
and exposure to dust, such as silica and aluminum, is widely
believed.3 In patients with secondary PAP, GM-CSF antibody is
not usually detected in the serum and BAL ﬂuid. In the case re-
ported by Hisata et al.,5 GM-CSF antibody was not detected in
the serum, and an electron probe X-ray microanalysis of the
lung biopsy samples showed a deposition of silica and aluminum.
This case further suggests the relationship between secondary
PAP and dust exposure. In our study, all patients with PAP were
diagnosed as having aPAP, due to the ﬁndings of positive GM-
CSF antibodies in the serum. Although the relationship between
dust exposure and aPAP is not clariﬁed,7 Inoue et al. has reported
that 26% of patients with aPAP had a history of dust exposure.4
Furthermore, the presence of GM-CSF antibody was not conﬁrmed
in the majority of cases diagnosed as secondary PAP including thevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 1
Characteristics of patients with autoimmune pulmonary alveolar proteinosis before
and after the disaster.
Total (n ¼ 8) Before the Disaster
(n ¼ 1)
After the Disaster
(n ¼ 7)
Age (yr) 51.6 ± 7.4 21 55.9 ± 7.1
Gender (M/F) 5/3 1/0 4/3
Smoking (C/F/N) 1/2/5 0/1/0 1/1/5
WBC (/mm3) 7757 ± 1093 5300 7680 ± 1259
LDH (IU/L) 302 ± 41.8 158 312 ± 46.8
CRP (mg/dL) 0.44 ± 0.25 0.03 0.50 ± 0.28
ESR (mm/hr) 9.5 ± 3.5 0 10.4 ± 3.7
KL-6 (IU/L) 7298 ± 3375 4470 7699 ± 3870
SP-A (ng/mL) 159.5 ± 38.0 70.0 168.1 ± 42.8
SP-D (ng/mL) 183.2 ± 38.2 169.9 182.1 ± 44.1
CEA (ng/mL) 20.7 ± 9.6 4.3 22.7 ± 10.8
PaO2 (Torr) (room air) 68.4 ± 3.7 82.2 66.8 ± 3.9
VC (L) 3.02 ± 0.37 4.99 2.69 ± 0.19
%VC (%) 85.4 ± 8.4 105.5 82.4 ± 9.1
Before the Disaster: fromMarch 11, 2007 toMarch 10, 2011, After the Disaster: from
March 11, 2011 to March 10, 2015. C/F/N, Current/Ex/Never smoker; WBC, white
blood cells; LDH, lactate dehydrogenase; CRP, C-reactive protein; ESR, erythrocyte
sedimentation rate; KL-6, Krebs von den Lungen-6; SP-A, surfactant protein-A;
SP-D, surfactant protein-D; CEA, carcinoembryonic antigen; PaO2, arterial partial
pressure of oxygen; VC, vital capacity. Mean ± SEM.
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ported a case of aPAP after indium-tin oxide exposure,8 and it has
been recently demonstrated that 34.2% of patients with aPAP had
a history of occupational inhalational exposure.9 We also evalu-
ated smoking history, because aPAP is reported to have some rela-
tion with smoking.4,10 In seven patients who had developed aPAP
after the disaster, ﬁve did not have smoking history and one had
quitted smoking more than 30 years before the disaster. The
remaining one patient had stopped smoking immediately after
the disaster, but resumed smoking after one month. These results
suggest that smoking did not affect the development of aPAP in
most patients.
Our hospital is located inland of northern Fukushima Prefecture
and did not experience a tsunami; however, many houses in the
area suffered construction or interior damage, such as wall cracks
and roof collapse. Although it is difﬁcult to draw a conclusion, these
facts also suggest the possibility that dust exposure may be the
trigger of aPAP development.
In summary, a signiﬁcant increase in the number of patients
with aPAP was observed after the 2011 Fukushima Disaster.
Although the pathogenesis of aPAP has not been fully clariﬁed,
the results of this study provide the further evidence on the rela-
tionship between aPAP and dust inhalation. In the future, further
investigations such as analysis of geneeenvironment interaction
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